DNA Methylation, Aging, and Cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and conceptual models without original data or systematic review methodology
PubMed 40558829 · doi:10.3390/epigenomes9020018
What was done
This narrative review synthesized literature on the intersection of aging, DNA methylation alterations, and cancer development. It examined molecular mechanisms including DNA methylation drift, entropy, epigenetic mosaicism, epiallelic shifts, epigenetic clocks, and potential clinical biomarker applications.
What was found
The abstract presents no quantitative data or effect sizes. It qualitatively describes how aging tissues experience both global hypomethylation and focal hypermethylation, leading to cumulative stochastic methylation errors, gene silencing, and increased susceptibility to oncogenesis, framing cancer as a condition of accelerated epigenetic aging.
Why it matters
It provides a unifying framework connecting chronological aging, epigenetic instability, and oncogenesis, advocating for age-informed paradigms in cancer biomarker development and therapeutics.
Limits
The paper is a non-systematic narrative review providing no primary experimental data, meta-analytic calculations, or defined search methodology. No specific datasets, cohorts, or quantitative performance metrics for epigenetic clocks are reported in the abstract.
Cited by
- supports With aging, genomic CpG sites that typically have methylation lose it, while CpG sites that typically lack methylation gain it.